Equities Analysts Issue Forecasts for AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a research report issued to clients and investors on Thursday, February 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.06) per share for the quarter, down from their prior forecast of ($0.85). HC Wainwright currently has a "Buy" rating and a $200.00 price objective on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics' Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($1.93) EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $2.43 EPS and Q4 2026 earnings at $3.82 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

A number of other research firms have also issued reports on AXSM. Morgan Stanley raised their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a report on Thursday. Bank of America boosted their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Robert W. Baird set a $132.00 price target on Axsome Therapeutics in a research note on Monday, February 3rd. Wells Fargo & Company boosted their price target on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada upped their target price on Axsome Therapeutics from $143.00 to $192.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $165.36.

Axsome Therapeutics Stock Performance

Shares of AXSM stock traded down $1.92 during mid-day trading on Monday, hitting $126.41. 587,375 shares of the stock were exchanged, compared to its average volume of 1,086,646. The stock's fifty day simple moving average is $103.53 and its two-hundred day simple moving average is $95.85. The stock has a market capitalization of $6.16 billion, a price-to-earnings ratio of -21.10 and a beta of 1.05. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Raiffeisen Bank International AG acquired a new position in Axsome Therapeutics in the fourth quarter valued at about $51,000. Assetmark Inc. acquired a new position in Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics in the fourth quarter valued at about $64,000. Aquatic Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $76,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $86,000. Institutional investors own 81.49% of the company's stock.

Insider Activity

In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.40% of the stock is owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.